China recalls leukemia drugs

Another Chinese product bites the dust. This time, authorities have recalled tainted leukemia drugs that caused leg pain and other reactions. The recall took place in late July but it's only now being reported by China's state-controlled media.

Though it's late, the timing of the news couldn't be better otherwise. A U.S. delegation, dispatched by the Department of Health and Human Services, just arrived in Beijing to negotiate drug and food safety agreements. It's the delegation's second visit, part of an effort to strengthen safety procedures there and to increase cooperation among U.S. and Chinese food-and-drug regulators.

- see this statement on the meetings
- read more from the International Herald Tribune

Related Articles:
New investigation underscores distrust of China. Report
China to overhaul drug safety regulations. Report
Chinese researcher helped shake up corrupt drug agency. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.